Neuralstem ALS Trial Principal Investigator To Speak At Brookings Institution

Jun 04, 2010, 07:53 ET from Neuralstem, Inc.

ROCKVILLE, Md., June 4 /PRNewswire-FirstCall/ -- Neuralstem, Inc. (NYSE Amex: CUR) announced that Dr. Eva Feldman, the Principal Investigator of its Phase I clinical trial to treat ALS (Amyotrophic Lateral Sclerosis, or Lou Gehrig's disease) with its spinal cord stem cells, will present at the inaugural A. Alfred Taubman Forum on Improving Science and Technology Innovation in the United States, on June 8, 2010, at The Brookings Institution in Washington, D.C.  Dr. Feldman, PhD, MD, is the Russell DeJong Professor of Neurology and Director of the ALS Clinic, University of Michigan.

(Logo: )

Dr. Feldman's 10:00 AM talk will address the importance of medical research at academic centers to keep America at the forefront of innovation, of which the ALS trial is an example. As part of the talk, she will discuss some general aspects of the trial, which will evaluate the safety of Neuralstem's spinal cord stem cells and the transplantation  procedure in up to 18 patients.

For more information on the event, please go to:

About Neuralstem, Inc.

Neuralstem's patented technology enables, for the first time, the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. The company is targeting major central nervous system diseases including: Ischemic Spastic Paraplegia, Traumatic Spinal Cord Injury, Huntington's disease and Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's disease. ALS is a progressive fatal neurodegenerative disease that affects nerve cells in the brain, leading to the degeneration and death of the motor neurons in the spinal cord that control muscle movement. Neuralstem is in a Phase I clinical trial to treat ALS.  For more information, please go to

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward- looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem's periodic reports, including the annual report on Form 10-KSB for the year ended December 31, 2009 and the quarterly report on Form 10-Q for the quarter ended March 31, 2010.

SOURCE Neuralstem, Inc.